Re: ZEN-3694 Single Agent Trial Status

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7656 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: ZEN-3694 Single Agent Trial Status

in response to

Re: ZEN-3694 Single Agent Trial Status

Toinv

posted on Sep 18, 2017 11:17PM

Anyone want to make bets on which company announces a deal first. Zenith or RVX? Or, is there a deal for both companies announced?

I say Zenith first.

This is just speculation.

tada

6 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply